Lv1
30 积分 2021-08-25 加入
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
17天前
已完结
Mechanisms and regulation of DNA end resection in the maintenance of genome stability
21天前
已完结
Targeting DNA damage response pathways in cancer
21天前
已完结
Pathophysiologic and Pharmacologic Considerations to Improve the Design and Application of Antibody-Drug Conjugates
21天前
已完结
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
21天前
已完结
HER2-targeted therapies beyond breast cancer - an update
21天前
已完结
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
21天前
已完结
Advances in systemic therapies for triple negative breast cancer
21天前
已完结
Neoadjuvant treatment of HER2-positive breast cancer: has the era of antibody-drug conjugates arrived?
21天前
已完结
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial
26天前
已完结
皖公网安备34019202002308